The role of phosphodiesterase inhibitors in urology in treatment of erectile dysfunction

Česká verzia

Authors: T. S. Hakky; A. Baumgarten; J. Beilan; Y. Zheng; D. Martinez; R. E. Carrion
Published in the journal: Urol List 2013; 11(1): 6-10

Summary

Erectile dysfunction (ED) rates are increasing worldwide and healthcare providers are increasingly prescribing PDE5 inhibitors and therapy for ED. The role of PDE5 inhibitors in urology is still evolving; as studies suggest that PDE 5 inhibitors have potentiating effects in the management of hypogonadism and BPH. This review evaluates the urologic impact and use of sildenafil, vardenafil, tadalfil and avanafil.

Key words:
phosphodiesterase inhibitor, erectile dysfunction, PDE5, sildenafil, tadalafil, avanafil, vardenafil

Zdroje

1. Setter SM, Iltz JL, Fincham JE et al. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother 2005; 39(7–8): 1286–1295.

2. Lue TF, Hon S. Pathophysiology of Erectile Dysfunction. Campbell-Walsh Urology: Elsevier Inc. 2000: 688–670.

3. Houry SK, Harlip IS. Sexual Dysfunction in Men and Women. Sexual Medicine 2010: 19–22.

4. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84(1): 50–56.

5. Crowe SM, Streetman DS. Vardenafil treatment for erectile dysfunction. Ann Pharmacother 2004; 38(1): 77–85.

6. Limin M, Johnsen N, Hellstrom WJG. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2010; 19(11): 1427–1437.

7. Alwaal A, Al-Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Devel Ther 2011; 5: 435–443.

8. Kuthe A. Phosphodiesterase 5 inhibitors in male sexual dysfunction. Curr Opin Urol 2003; 13(5): 405–410.

9. Basu A, Ryder REJ. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004; 64(23): 2667–288.

10. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338(20): 1397–1404.

11. Saenz de Tejada I, Frutos JA, Gaudo M et al. Comparative selectivity: profiles of tadalafil, sildenafil and vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res 2002; 14: S20–S32.

12. Porst H. IC351 (tadalafil, Cialis): update on clinicalexperience. Int J Impot Re 2002; 14 (Suppl 1): S57–S64.

13. Hellstrom WJG, Gittleman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23(6): 763–771.

14. Carson CC. Cardiacsafety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 2005; 96(12B): 37M–41M.

15. Eardley I, Cartledge J. Tadalafil (Cialis) formewitherectiledysfunction. Int J Clin Pract 2002; 56(4): 300–304.

16. Brock GB. Tadalafil: a new agent for erectile dysfunction. Can J Urol 2003; 10 (Suppl 1): 17–22.

17. Briganti AA, Salonia F, Deho G et al. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. World J Urol 2005; 23(6): 374–384.

18. Brock GB, Mcmahon BG, Chen KK et all. Efficacy and safety of Tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168 (4 Pt 1): 1332–1336.

19. Gacci M, Corona G, Salvi M et al. A systematicreview and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61(5): 994–1003.

20. Andersson KE, de Groat WC, McVary KT et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011; 30(3): 292–301.

21. Kaplan SA. Tadalafil for theTreatment of Benign Prostatic Hyperplasia: When the Moment Does Not Add Up. Eur Urol 2013; 63(3): 517–578.

22. Tuncel A, Nalcacioglu V, Ener K et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010; 28(1): 17–22.

23. Clinical practice guidelines. Management of BPH (revised, 2010). AmericanUrologicalAssociation. http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm?sub=bph.

24. Oelke M, Bachmann A, Descazeaud A et al. Guidelines on thetreatmentof non-neurogenic male LUTS. European Association of Urology. http://www.uroweb. org/gls/pdf/12_Male_LUTS.pdf.

25. Mills TM, Stopper VS, Wiedmeier VT. Effects of castration and androgen replacement on the hemodynamics of penile erection in therat. Biol Reprod 1994; 51(2): 234–238.

26. Penson DF, Ng C, Rajfer J. Adrenal control of erectile function and nitric oxide synthase in therat penis. Endocrinology 1997; 138(9): 3925–3932.

27. Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Can Urol Assoc J 2012; 6(4): 269–274.

28. Dimitriadis F, Tsambalas S, Tsounapi P et al. Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic in fertile men: a randomized trial. BJU Int 2010; 106(8): 1181–1185.

29. Basal S, Wambi C, Acikel C et al. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int 2012 [Epub ahead of print].

30. Kendirci M, Bejma J, Hellstrom WJ. Update on erectile dysfunction in prostate cancer patients. Curr Opin Urol 2006; 16(3): 186–195.

31. Padma-Nathan H, McCullough AR, Levine LA et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20(5): 479–486.

32. Salonia A, Gallina A, Zanni G et al. Acceptance of and discontinuation rate fro merectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 53(3): 564–570.